Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001178913-23-003607 Act: 33 Size: 155 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-003596 Act: 34 Size: 138 KB 网页链接
$Sol-gel(SLGL)$ 144 Report of proposed sale of securities Accession Number: 0001976408-23-000117 Act: 33 Size: 11 KB 网页链接
$Sol-gel(SLGL)$ 144 Report of proposed sale of securities Accession Number: 0001976408-23-000114 Act: 33 Size: 9 KB 网页链接
$Sol-gel(SLGL)$ 144 Report of proposed sale of securities Accession Number: 0001976408-23-000112 Act: 33 Size: 8 KB 网页链接
$Sol-gel(SLGL)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001178913-23-002803 Act: 33 Size: 568 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-002801 Act: 34 Size: 2 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-002589 Act: 34 Size: 17 KB 网页链接
$Sol-gel(SLGL)$ 144 Report of proposed sale of securities Accession Number: 0001976408-23-000052 Act: 33 Size: 8 KB 网页链接
$Sol-gel(SLGL)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-002503 Act: 34 Size: 12 KB 网页链接